docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2023-22-4-64-69docru-271Research ArticleЭНДОКРИНОЛОГИЯENDOCRINOLOGYПролактин как фактор, влияющий на течение новой коронавирусной инфекции: обзор литературыProlactin as a Factor Influencing the Course of a New Coronavirus Infection: a Literary Reviewhttps://orcid.org/0000-0002-2908-002XВоеводаС. М.VoevodaS. M.

Воевода Светлана Михайловна — к. м. н., младший научный сотрудник лаборатории клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний ; врач – лабораторный генетик исследовательско-диагностической лаборатории 

630089, г. Новосибирск, ул. Б. Богаткова, д. 175/1; 630117,  г. Новосибирск, 630117, ул. Тимакова, д. 2

175/1 B. Bogatkova Str., Novosibirsk,  630089;  2 Timatkova Str., Novosibirsk,  630117

sm.voevoda@mail.ruhttps://orcid.org/0000-0003-4095-0169РымарО. Д.RymarO. D.

Рымар Оксана Дмитриевна  — д. м. н., главный научный сотрудник с возложением обязанностей заведующего лабораторией клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний

630089, г. Новосибирск, ул. Б. Богаткова, д. 175/1

175/1 B. Bogatkova Str., Novosibirsk,  630089

orymar23@gmail.comНаучно-исследовательский институт терапии и профилактической медицины — филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики» СО РАН;РоссияResearch Institute of Therapy and Preventive Medicine – the branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Science; Federal Research Center for Fundamental and Translational MedicineRussian FederationНаучно-исследовательский институт терапии и профилактической медицины — филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики» СО РАН; ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины»РоссияResearch Institute of Therapy and Preventive Medicine – the branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of ScienceRussian Federation202319022025224КАРДИОМЕТАБОЛИЧЕСКАЯ МЕДИЦИНА6469Copyright © Воевода С.М., Рымар О.Д., 20252025Воевода С.М., Рымар О.Д.Voevoda S.M., Rymar O.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/271

Цель обзора: представить вероятные патофизиологические механизмы развития гиперпролактинемии у пациентов с новой коронавирусной инфекцией, а также результаты доступных на момент написания обзора клинических исследований по оценке вклада гиперпролактинемии в тяжесть течения коронавирусной инфекции. Гиперпролактинемия рассматривается как негативный фактор, способствующий более тяжелому течению коронавирусной инфекции у разных групп пациентов. В основе более тяжелого течения коронавирусной инфекции лежит развитие воспалительных процессов, усиливающихся при повышенном уровне пролактина в крови. Заключение. Авторы большинства исследовательских работ сообщают, что необходимы экспериментальные, клинические испытания и клинические исследования, чтобы подтвердить воспалительную и/или противовоспалительную роль пролактина в условиях коронавирусной инфекции. 

Aim

Aim: to present the likely pathophysiological mechanisms of hyperprolactinemia development in patients with a new coronavirus infection, as well as to present the results of clinical studies available at the time of writing the review to assess the contribution of hyperprolactinemia to the severity of the coronavirus infection.

Key points

Key points: hyperprolactinemia is considered as a negative factor contributing to a more severe course of coronavirus infection in different groups of patients. The more severe course of a covid infection is based on the development of inflammatory processes that increase with an increased level of prolactin in the blood.

Conclusion

Conclusion. The authors of most research papers report that experimental, clinical trials and clinical studies are needed to confirm the inflammatory and/or anti-inflammatory role of prolactin in the setting of coronavirus infection. 

пролактингиперпролактинемияновая коронавирусная инфекцияprolactinhyperprolactinemianew coronavirus infectionReferencesВоевода М.И., Фомичева М.Л. Все о коронавирусе COVID-19. М; 2020. 92 с.Voevoda M.I., Fomicheva M.L. All about the coronavirus COVID-19. Moscow; 2020. 92 p.Ivanisenko V.A., Gaisler E.V., Basov N.V. et al. Plasma metabolomics and gene regulatory networks analysis reveal the role of nonstructural SARS-CoV-2 viral proteins in metabolic dysregulation in COVID-19 patients. Sci. Rep. 2022;12:19977. DOI: 10.1038/s41598-022-24170-0Ivanisenko V.A., Gaisler E.V., Basov N.V. et al. Plasma metabolomics and gene regulatory networks analysis reveal the role of nonstructural SARS-CoV-2 viral proteins in metabolic dysregulation in COVID-19 patients. Sci. Rep. 2022;12:19977. DOI: 10.1038/s41598-022-24170-0Rasheed H.A., Al-Kuraishy H.M., Al-Gareeb A.I. et al. Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon. J. Adv. Pharm. Technol. Res. 2019;10(4):163–168. DOI: 10.4103/japtr.JAPTR_65_19Rasheed H.A., Al-Kuraishy H.M., Al-Gareeb A.I. et al. Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon. J. Adv. Pharm. Technol. Res. 2019;10(4):163–168. DOI: 10.4103/japtr.JAPTR_65_19Grattan D.R. Coordination or coincidence? The relationship between prolactin and gonadotropin secretion. Trends Endocrinol. Metab. 2018;29(1):3–5. DOI: 10.1016/j.tem.2017.11.004Grattan D.R. Coordination or coincidence? The relationship between prolactin and gonadotropin secretion. Trends Endocrinol. Metab. 2018;29(1):3–5. DOI: 10.1016/j.tem.2017.11.004Costello L.C., Franklin R.B. Testosterone, prolactin, and oncogenic regulation of the prostate gland. A new concept: testosteroneindependent malignancy is the development of prolactin-dependent malignancy. Oncol. Rev. 2018;12(2):356. DOI: 10.4081/oncol.2018.356Costello L.C., Franklin R.B. Testosterone, prolactin, and oncogenic regulation of the prostate gland. A new concept: testosteroneindependent malignancy is the development of prolactin-dependent malignancy. Oncol. Rev. 2018;12(2):356. DOI: 10.4081/oncol.2018.356Bern H.A., Nicoll C.S. The comparative endocrinology of prolactin. Rec. Prog. Horm. Res. 1968;24:681–720. DOI: 10.1016/b978-1- 4831-9827-9.50019-8Bern H.A., Nicoll C.S. The comparative endocrinology of prolactin. Rec. Prog. Horm. Res. 1968;24:681–720. DOI: 10.1016/b978-1- 4831-9827-9.50019-8Воевода С.М., Щербакова Л.В., Денисова Д.В. и др. Связь атеросклероз-ассоциированных кардиоваскулярных факторов риска с разным уровнем пролактина у женщин репродуктивного возраста. Атеросклероз. 2018;14(4):67–72. DOI: 10.15372/ATER20180407Voevoda S.M., Shcherbakova L.V., Denisova D.V. et al. Association of atherosclerosisassociated cardiovascular risk factors with different levels of prolactin in women of reproductive age. Atherosclerosis. 2018;14(4):67–72. (in Russian). DOI: 10.15372/ATER20180407Рымар О.Д., Воевода С.М., Шахшнейдер Е.В. и др. Частота метаболического синдрома и его отдельных компонентов у женщин 25–45 лет в зависимости от уровня пролактина. Ожирение и метаболизм. 2021;18(2):180–189. DOI: 10.14341/omet12475Rymar O.D., Voevoda S.M., Schachshneider E.V. The frequency of the metabolic syndrome and its individual components in women aged 25–45 depending on the level of prolactin. Obesity and metabolism. 2021;18(2):180– 189. (in Russian). DOI: 10.14341/omet12475Blanco F.F., Legorreta H.M.V., Huerta V.Y.R. et al. Role of prolactin in the immune response. Bol. Med. Hosp. Infant. Mex. 2012;69(5):329–336.Blanco F.F., Legorreta H.M.V., Huerta V.Y.R. et al. Role of prolactin in the immune response. Bol. Med. Hosp. Infant. Mex. 2012;69(5):329–336.Aguilar-Rojas A., Huerta-Reyes M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells. Oncol. Rep. 2009.22(5):981–990. DOI: 10.3892/or_00000525Aguilar-Rojas A., Huerta-Reyes M. Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells. Oncol. Rep. 2009.22(5):981–990. DOI: 10.3892/or_00000525Yu-Lee L.-Y. Molecular actions of prolactin in the immune system. Proc. Soc. Exp. Biol. Med. 1997;215(1):35–52. DOI: 10.3181/00379727-215-44111Yu-Lee L.-Y. Molecular actions of prolactin in the immune system. Proc. Soc. Exp. Biol. Med. 1997;215(1):35–52. DOI: 10.3181/00379727-215-44111De Bellis A., Bizzarro A., Pivonello R. et al. Prolactin and autoimmunity. Pituitary. 2005;8(1):25–30. DOI: 10.1007/s11102-005-5082-5De Bellis A., Bizzarro A., Pivonello R. et al. Prolactin and autoimmunity. Pituitary. 2005;8(1):25–30. DOI: 10.1007/s11102-005-5082-5Bernard V., Young J., Binart N. Prolactin — a pleiotropic factor in health and disease. Nat. Rev. Endocrinol. 2019;15(6):356–365. DOI: 10.1038/s41574-019-0194-6Bernard V., Young J., Binart N. Prolactin — a pleiotropic factor in health and disease. Nat. Rev. Endocrinol. 2019;15(6):356–365. DOI: 10.1038/s41574-019-0194-6Yip S., Romano N., Gustafson P. et al. Elevated prolactin during pregnancy drives a phenotypic switch in mouse hypothalamic dopaminergic neurons. Cell Rep. 2019;26(7):1787–1799. DOI: 10.1016/j.celrep.2019.01.067Yip S., Romano N., Gustafson P. et al. Elevated prolactin during pregnancy drives a phenotypic switch in mouse hypothalamic dopaminergic neurons. Cell Rep. 2019;26(7):1787–1799. DOI: 10.1016/j.celrep.2019.01.067Gong N., Ferreira-Martins D., McCormick S. et al. Divergent genes encoding the putative receptors for growth hormone and prolactin in sea lamprey display distinct patterns of expression. Sci. Rep. 2020;10(1):1674. DOI: 10.1038/s41598-020-58344-5Gong N., Ferreira-Martins D., McCormick S. et al. Divergent genes encoding the putative receptors for growth hormone and prolactin in sea lamprey display distinct patterns of expression. Sci. Rep. 2020;10(1):1674. DOI: 10.1038/s41598-020-58344-5Al-Kuraishy H.M., Al-Gareeb A.I., Awad M.S. et al. Assessment of serum prolactin levels in acute myocardial infarction: the role of pharmacotherapy. Ind. J. Endocrinol. Metab. 2016. 20(1):72– 79. DOI: 10.4103/2230-8210.172240 1Al-Kuraishy H.M., Al-Gareeb A.I., Awad M.S. et al. Assessment of serum prolactin levels in acute myocardial infarction: the role of pharmacotherapy. Ind. J. Endocrinol. Metab. 2016. 20(1):72– 79. DOI: 10.4103/2230-8210.172240 1Liu Y., Jiang J., Lepik B. et al. Subdomain 2, not the transmembrane domain, determines the dimerization partner of growth hormone receptor and prolactin receptor. Endocrinology. 2017;158(10):3235– 3248. DOI: 10.1210/en.2017-00469Liu Y., Jiang J., Lepik B. et al. Subdomain 2, not the transmembrane domain, determines the dimerization partner of growth hormone receptor and prolactin receptor. Endocrinology. 2017;158(10):3235– 3248. DOI: 10.1210/en.2017-00469Aoki M., Wartenberg P., Grünewald R. et al. Widespread cell-specific prolactin receptor expression in multiple murine organs. Endocrinology. 2019;160(11):2587–2599. DOI: 10.1210/en.2019-00234Aoki M., Wartenberg P., Grünewald R. et al. Widespread cell-specific prolactin receptor expression in multiple murine organs. Endocrinology. 2019;160(11):2587–2599. DOI: 10.1210/en.2019-00234Sykes L., MacIntyre D.A., Yap X.J. et al. Changes in the Th1: Th2 cytokine bias in pregnancy and the effects of the anti-inflammatory cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2. Mediators Inflamm. 2012;2012:416739. DOI: 10.1155/2012/4167 39.10.1155/2012/416739Sykes L., MacIntyre D.A., Yap X.J. et al. Changes in the Th1: Th2 cytokine bias in pregnancy and the effects of the anti-inflammatory cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2. Mediators Inflamm. 2012;2012:416739. DOI: 10.1155/2012/4167 39.10.1155/2012/416739Parra J., Ramírez-Peredo E., et al. Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. Hematology. 2012;17(2):85–92. DOI: 10.1179/102453312X13221316477930Parra J., Ramírez-Peredo E., et al. Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus-host disease after allogeneic stem cell transplantation. Hematology. 2012;17(2):85–92. DOI: 10.1179/102453312X13221316477930Yu-Lee L.-Y. Prolactin modulation of immune and inflammatory responses. Recent Prog. Horm. Res. 2002;57:435–455. DOI: 0.1210/ rp.57.1.435Yu-Lee L.-Y. Prolactin modulation of immune and inflammatory responses. Recent Prog. Horm. Res. 2002;57:435–455. DOI: 0.1210/ rp.57.1.435Chuang E., Molitch M. Prolactin and autoimmune diseases in humans. Acta Biomed. 2007;78(Suppl 1):255–261.Chuang E., Molitch M. Prolactin and autoimmune diseases in humans. Acta Biomed. 2007;78(Suppl 1):255–261.Adán N., Guzmán-Morales J., Ledesma-Colunga M.G. et al. Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis. J. Clin. Invest. 2013;123(9):3902–3913. DOI: 10.1172/JCI69485Adán N., Guzmán-Morales J., Ledesma-Colunga M.G. et al. Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis. J. Clin. Invest. 2013;123(9):3902–3913. DOI: 10.1172/JCI69485Imrich R. The role of neuroendocrine system in the pathogenesis of rheumatic disease (minireview). Endocr. Regul. 2002.36(2):95–106.Imrich R. The role of neuroendocrine system in the pathogenesis of rheumatic disease (minireview). Endocr. Regul. 2002.36(2):95–106.Shelly S., Boaz M., Orbach H. Prolactin and autoimmunity. Autoimmun. Rev. 2011;11 (6–7):A465–A470. DOI: 10.1016/j.autrev.2011.11.009Shelly S., Boaz M., Orbach H. Prolactin and autoimmunity. Autoimmun. Rev. 2011;11 (6–7):A465–A470. DOI: 10.1016/j.autrev.2011.11.009Wu X., Liu Y., Guo X. et al. Prolactin inhibits the progression of intervertebral disc degeneration through inactivation of the NF-κB pathway in rats. Cell Death Dis. 2018;9(2):98. DOI: 10.1038/ s41419-017-0151-zWu X., Liu Y., Guo X. et al. Prolactin inhibits the progression of intervertebral disc degeneration through inactivation of the NF-κB pathway in rats. Cell Death Dis. 2018;9(2):98. DOI: 10.1038/ s41419-017-0151-zBorba V., Zandman-Goddard G., Shoenfeld Y. Prolactin and autoimmunity: the hormone as an inflammatory cytokine. Best Pract. Res. Clin. Endocrinol. Metab. 2019;33(6):101324. DOI: 10.1016/j.beem.2019.101324Borba V., Zandman-Goddard G., Shoenfeld Y. Prolactin and autoimmunity: the hormone as an inflammatory cytokine. Best Pract. Res. Clin. Endocrinol. Metab. 2019;33(6):101324. DOI: 10.1016/j.beem.2019.101324Williams L., Sarma U., Willets K. et al. Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J. Biol. Chem. 2007;282(10):6965–6975. DOI: 10.1074/jbc.M609101200Williams L., Sarma U., Willets K. et al. Expression of constitutively active STAT3 can replicate the cytokine-suppressive activity of interleukin-10 in human primary macrophages. J. Biol. Chem. 2007;282(10):6965–6975. DOI: 10.1074/jbc.M609101200Tripathi A., Sodhi A. Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways. Int. Immunol. 2008;20(3):327–336. DOI: 10.1093/intimm/dxm145Tripathi A., Sodhi A. Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways. Int. Immunol. 2008;20(3):327–336. DOI: 10.1093/intimm/dxm145Retnoningrum D., Hendrianingtyas M., Istiadi H. et al. Correlation between prolactin serum with neutrophil lymphocyte ratio (NLR) in systemic inflammatory response syndrome. Diponegoro Int. Med. 2021;J2(1):10–13.Retnoningrum D., Hendrianingtyas M., Istiadi H. et al. Correlation between prolactin serum with neutrophil lymphocyte ratio (NLR) in systemic inflammatory response syndrome. Diponegoro Int. Med. 2021;J2(1):10–13.Wu W., Sun M., Zhang H. et al. Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation. Gut. 2014;63(12):1883–1892. DOI: 10.1136/gutjnl-2013-306083Wu W., Sun M., Zhang H. et al. Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation. Gut. 2014;63(12):1883–1892. DOI: 10.1136/gutjnl-2013-306083Al-Kuraishy H.M., Al-Gareeb A.I., Butnariu M. et al. The crucial role of prolactin-lactogenic hormone in COVID-19. Mol. Cell. Biochem. 2022. 477:1381–1392. DOI: 10.1007/s11010-022-04381-9Al-Kuraishy H.M., Al-Gareeb A.I., Butnariu M. et al. The crucial role of prolactin-lactogenic hormone in COVID-19. Mol. Cell. Biochem. 2022. 477:1381–1392. DOI: 10.1007/s11010-022-04381-9Barrett R., Narasimhulu C., Parthasarathy S. Adrenergic hormones induce extrapituitary prolactin gene expression in leukocytespotential implications in obesity. Sci. Rep. 2018; 8(1):1936. DOI: 10.1038/s41598-018-20378-1Barrett R., Narasimhulu C., Parthasarathy S. Adrenergic hormones induce extrapituitary prolactin gene expression in leukocytespotential implications in obesity. Sci. Rep. 2018; 8(1):1936. DOI: 10.1038/s41598-018-20378-1Al-Kuraishy H.M., Al-Gareeb A.I., Al-Maiahy T.J. Concept and connotation of oxidative stress in preeclampsia. J. Lab. Phys. 2018;10(3):276–282. DOI: 10.4103/JLP.JLP_26_18Al-Kuraishy H.M., Al-Gareeb A.I., Al-Maiahy T.J. Concept and connotation of oxidative stress in preeclampsia. J. Lab. Phys. 2018;10(3):276–282. DOI: 10.4103/JLP.JLP_26_18Буйваленко У.В., Перепелова М.А., Золотарева Р.А. и др. Болезни гипофиза и COVID-19: систематический обзор литературы. Проблемы эндокринологии. 2022;68(5):14–23. DOI: 10.14341/probl13108Buyvalenko U.V., Perepelova M.A., Zolotareva R.A. et al. Pituitary disease and COVID-19: a systematic review of the literature. Problems of Endocrinology. 2022;68(5):14–23. (in Russian). DOI: 10.14341/probl13108Jin J.M., Bai P., He W. et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. DOI: 10.3389/fpubh.2020.00152Jin J.M., Bai P., He W. et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. DOI: 10.3389/fpubh.2020.00152Liu D., Li L., Wu X. et al. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: а preliminary analysis. Am. J. Roentgenol. 2020; 215(1):127–132. DOI: 10.2214/AJR.20.23072Liu D., Li L., Wu X. et al. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: а preliminary analysis. Am. J. Roentgenol. 2020; 215(1):127–132. DOI: 10.2214/AJR.20.23072Liu H., Wang L.-L., Zhao S.-J. et al. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J. Reprod. Immunol. 2020;139:103122. DOI: 10.1016/j.jri.2020.103122Liu H., Wang L.-L., Zhao S.-J. et al. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J. Reprod. Immunol. 2020;139:103122. DOI: 10.1016/j.jri.2020.103122Fuxe K., Andersson K., Enroth P. et al. Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications. Psychoneuroendocrinology. 1989;14(1–2):19–41. DOI: 10.1016/0306-4530(89)90054-1Fuxe K., Andersson K., Enroth P. et al. Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications. Psychoneuroendocrinology. 1989;14(1–2):19–41. DOI: 10.1016/0306-4530(89)90054-1Bevelacqua J.J., Masoompour S.M., Mortazavi S.A.R., Mortazavi S.M.J. Why do some reports claim that the number of COVID-19 hospitalized smokers is smaller than expected? J. Biomed. Phys. Eng. 2020;10(5):659–662. DOI: 10.31661/jbpe.v0i0.2007-1144Bevelacqua J.J., Masoompour S.M., Mortazavi S.A.R., Mortazavi S.M.J. Why do some reports claim that the number of COVID-19 hospitalized smokers is smaller than expected? J. Biomed. Phys. Eng. 2020;10(5):659–662. DOI: 10.31661/jbpe.v0i0.2007-1144González-Rubio J., Navarro-López C., López-Nájera E. et al. A systematic review and meta-analysis of hospitalised current smokers and COVID-19. Int. J. Environ. Res. Public Health. 2020;17(20):7394. DOI: 10.3390/ijerph17207394González-Rubio J., Navarro-López C., López-Nájera E. et al. A systematic review and meta-analysis of hospitalised current smokers and COVID-19. Int. J. Environ. Res. Public Health. 2020;17(20):7394. DOI: 10.3390/ijerph17207394Petrulli J.R., Kalish B., Nabulsi N.B. et al. Systemic inflammation enhances stimulant-induced striatal dopamine elevation. Transl. Psychiatry. 2017;7(3):e1076. DOI: 10.1038/tp.2017.18Petrulli J.R., Kalish B., Nabulsi N.B. et al. Systemic inflammation enhances stimulant-induced striatal dopamine elevation. Transl. Psychiatry. 2017;7(3):e1076. DOI: 10.1038/tp.2017.18Jara L.J., López-Zamora B., Ordoñez-González I. et al. The immuneneuroendocrine system in COVID-19, advanced age and rheumatic diseases. Autoimmun. Rev. 2021;20(11):102946. DOI: 10.1016/j. autrev.2021.102946Jara L.J., López-Zamora B., Ordoñez-González I. et al. The immuneneuroendocrine system in COVID-19, advanced age and rheumatic diseases. Autoimmun. Rev. 2021;20(11):102946. DOI: 10.1016/j. autrev.2021.102946Li Y.-C., Bai W-Z., Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. 2020;92(6):552–555. DOI: 10.1002/jmv.25728Li Y.-C., Bai W-Z., Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. 2020;92(6):552–555. DOI: 10.1002/jmv.25728Pawlak R., Napiorkowska-Pawlak D., Takada Y. et al. The differential effect of angiotensin II and angiotensin 1-7 on norepinephrine, epinephrine, and dopamine concentrations in rat hypothalamus: the involvement of angiotensin receptors. Brain Res. Bull. 2001;54(6):689–694. DOI: 10.1016/S0361-9230(01)00489-0Pawlak R., Napiorkowska-Pawlak D., Takada Y. et al. The differential effect of angiotensin II and angiotensin 1-7 on norepinephrine, epinephrine, and dopamine concentrations in rat hypothalamus: the involvement of angiotensin receptors. Brain Res. Bull. 2001;54(6):689–694. DOI: 10.1016/S0361-9230(01)00489-0Banday A.A., Diaz A.D., Lokhandwala M. Kidney dopamine D1-like receptors and angiotensin 1-7 interaction inhibits renal Na+ transporters. Am. J. Physiol. Renal. Physiol. 2019;317(4):F949– F956. DOI: 10.1152/ajprenal.00135.2019Banday A.A., Diaz A.D., Lokhandwala M. Kidney dopamine D1-like receptors and angiotensin 1-7 interaction inhibits renal Na+ transporters. Am. J. Physiol. Renal. Physiol. 2019;317(4):F949– F956. DOI: 10.1152/ajprenal.00135.2019

The authors declare that there are no conflicts of interest present.